FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740762562> ?p ?o ?g. }

• W2740762562 endingPage "1242" @default.
• W2740762562 startingPage "1234" @default.
• W2740762562 abstract "To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa).In a phase 1/2 study, patients with advanced localized PCa were sequentially treated with 70 to 74 Gy to the prostate and dose-escalating PLN-IMRT at doses of 50 Gy (cohort 1), 55 Gy (cohort 2), and 60 Gy (cohort 3) in 35 to 37 fractions. Two hypofractionated cohorts received 60 Gy to the prostate and 47 Gy to PLN in 20 fractions over 4 weeks (cohort 4) and 5 weeks (cohort 5). All patients received long-course androgen deprivation therapy. Primary outcome was late Radiation Therapy Oncology Group toxicity at 2 years after radiation therapy for all cohorts. Secondary outcomes were acute and late toxicity using other clinician/patient-reported instruments and treatment efficacy.Between August 9, 2000, and June 9, 2010, 447 patients were enrolled. Median follow-up was 90 months. The 2-year rates of grade 2+ bowel/bladder toxicity were as follows: cohort 1, 8.3%/4.2% (95% confidence interval 2.2%-29.4%/0.6%-26.1%); cohort 2, 8.9%/5.9% (4.1%-18.7%/2.3%-15.0%); cohort 3, 13.2%/2.9% (8.6%-20.2%/1.1%-7.7%); cohort 4, 16.4%/4.8% (9.2%-28.4%/1.6%-14.3%); cohort 5, 12.2%/7.3% (7.6%-19.5%/3.9%-13.6%). Prevalence of bowel and bladder toxicity seemed to be stable over time. Other scales mirrored these results. The biochemical/clinical failure-free rate was 71% (66%-75%) at 5 years for the whole group, with pelvic lymph node control in 94% of patients.This study shows the safety and tolerability of PLN-IMRT. Ongoing and planned phase 3 studies will need to demonstrate an increase in efficacy using PLN-IMRT to offset the small increase in bowel side effects compared with prostate-only IMRT." @default.
• W2740762562 created "2017-08-08" @default.
• W2740762562 creator A5003388016 @default.
• W2740762562 creator A5009984723 @default.
• W2740762562 creator A5011222815 @default.
• W2740762562 creator A5011330633 @default.
• W2740762562 creator A5012480876 @default.
• W2740762562 creator A5025921361 @default.
• W2740762562 creator A5033672260 @default.
• W2740762562 creator A5035228430 @default.
• W2740762562 creator A5038283257 @default.
• W2740762562 creator A5047234703 @default.
• W2740762562 creator A5059460174 @default.
• W2740762562 creator A5075155704 @default.
• W2740762562 creator A5080362183 @default.
• W2740762562 creator A5088376729 @default.
• W2740762562 date "2017-12-01" @default.
• W2740762562 modified "2023-10-15" @default.
• W2740762562 title "Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer" @default.
• W2740762562 cites W182655838 @default.
• W2740762562 cites W1978152932 @default.
• W2740762562 cites W1980080809 @default.
• W2740762562 cites W1980789427 @default.
• W2740762562 cites W2006988918 @default.
• W2740762562 cites W2008090769 @default.
• W2740762562 cites W2022305828 @default.
• W2740762562 cites W2037524819 @default.
• W2740762562 cites W2038449783 @default.
• W2740762562 cites W2043945205 @default.
• W2740762562 cites W2063266750 @default.
• W2740762562 cites W2088021312 @default.
• W2740762562 cites W2099051717 @default.
• W2740762562 cites W2100903925 @default.
• W2740762562 cites W2112784445 @default.
• W2740762562 cites W2129656462 @default.
• W2740762562 cites W2131398800 @default.
• W2740762562 cites W2145140579 @default.
• W2740762562 cites W2147988554 @default.
• W2740762562 cites W2150992971 @default.
• W2740762562 cites W2172029087 @default.
• W2740762562 cites W2176970460 @default.
• W2740762562 cites W2214621962 @default.
• W2740762562 cites W2225329187 @default.
• W2740762562 cites W2346316361 @default.
• W2740762562 cites W2465092116 @default.
• W2740762562 cites W2553178344 @default.
• W2740762562 cites W4205151458 @default.
• W2740762562 doi "https://doi.org/10.1016/j.ijrobp.2017.07.041" @default.
• W2740762562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5697895" @default.
• W2740762562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28939224" @default.
• W2740762562 hasPublicationYear "2017" @default.
• W2740762562 type Work @default.
• W2740762562 sameAs 2740762562 @default.
• W2740762562 citedByCount "32" @default.
• W2740762562 countsByYear W27407625622018 @default.
• W2740762562 countsByYear W27407625622019 @default.
• W2740762562 countsByYear W27407625622020 @default.
• W2740762562 countsByYear W27407625622021 @default.
• W2740762562 countsByYear W27407625622022 @default.
• W2740762562 countsByYear W27407625622023 @default.
• W2740762562 crossrefType "journal-article" @default.
• W2740762562 hasAuthorship W2740762562A5003388016 @default.
• W2740762562 hasAuthorship W2740762562A5009984723 @default.
• W2740762562 hasAuthorship W2740762562A5011222815 @default.
• W2740762562 hasAuthorship W2740762562A5011330633 @default.
• W2740762562 hasAuthorship W2740762562A5012480876 @default.
• W2740762562 hasAuthorship W2740762562A5025921361 @default.
• W2740762562 hasAuthorship W2740762562A5033672260 @default.
• W2740762562 hasAuthorship W2740762562A5035228430 @default.
• W2740762562 hasAuthorship W2740762562A5038283257 @default.
• W2740762562 hasAuthorship W2740762562A5047234703 @default.
• W2740762562 hasAuthorship W2740762562A5059460174 @default.
• W2740762562 hasAuthorship W2740762562A5075155704 @default.
• W2740762562 hasAuthorship W2740762562A5080362183 @default.
• W2740762562 hasAuthorship W2740762562A5088376729 @default.
• W2740762562 hasBestOaLocation W27407625621 @default.
• W2740762562 hasConcept C121608353 @default.
• W2740762562 hasConcept C126322002 @default.
• W2740762562 hasConcept C126894567 @default.
• W2740762562 hasConcept C141071460 @default.
• W2740762562 hasConcept C143998085 @default.
• W2740762562 hasConcept C2776235491 @default.
• W2740762562 hasConcept C2777899217 @default.
• W2740762562 hasConcept C2780192828 @default.
• W2740762562 hasConcept C509974204 @default.
• W2740762562 hasConcept C71924100 @default.
• W2740762562 hasConcept C72563966 @default.
• W2740762562 hasConceptScore W2740762562C121608353 @default.
• W2740762562 hasConceptScore W2740762562C126322002 @default.
• W2740762562 hasConceptScore W2740762562C126894567 @default.
• W2740762562 hasConceptScore W2740762562C141071460 @default.
• W2740762562 hasConceptScore W2740762562C143998085 @default.
• W2740762562 hasConceptScore W2740762562C2776235491 @default.
• W2740762562 hasConceptScore W2740762562C2777899217 @default.
• W2740762562 hasConceptScore W2740762562C2780192828 @default.
• W2740762562 hasConceptScore W2740762562C509974204 @default.
• W2740762562 hasConceptScore W2740762562C71924100 @default.
• W2740762562 hasConceptScore W2740762562C72563966 @default.

• next